Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Breast Neoplasms 4Brain Neoplasms 3von Hippel-Lindau Disease 1Tonsillar Neoplasms 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Diseases 1Neoplastic Cells, Circulating 1Hemangioblastoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1

Interventions

motexafin gadolinium 1irinotecan sucrosofate 1bemcentinib 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy 1Radiation 1Procarbazine 1Postoperative Period 1Pemetrexed 1Nivolumab 1Methotrexate 1Memantine 1Irinotecan 1Immunotherapy 1Donepezil 1Cytarabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Central Nervous System Neoplasms × Bevacizumab × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡